Cardiac evaluation of mitoxantrone.

Journal Article

Mitoxantrone is a synthetic anthraquinone that was developed through the doxorubicin analog program in hopes of retaining anticancer activity with less cardiotoxicity. This study evaluated 18 patients receiving mitoxantrone with serial noninvasive tests of left ventricular function and with endomyocardial biopsy. The echocardiograms and systolic time intervals demonstrated a trend to deterioration that did not achieve statistical significance. However, the nuclear angiographic ejection fraction significantly decreased from 61% +/- 6% (means +/- SD) at baseline to 58% +/- 5% (P less than 0.05) after 48 mg/m2 of mitoxantrone. The endomyocardial biopsies revealed tubular swelling, degeneration of mitochondria, minimal chromatin clumping, and myofibrillar lysis. This study has revealed mild but definite impairment of cardiac function and mild changes of myocardial morphology during mitoxantrone therapy. Although mitoxantrone is an effective chemotherapeutic agent, a direct comparison of mitoxantrone with doxorubicin is necessary to compare relative therapeutic to cardiotoxic ratios.

Full Text

Duke Authors

Cited Authors

  • Unverferth, DV; Unverferth, BJ; Balcerzak, SP; Bashore, TA; Neidhart, JA

Published Date

  • April 1, 1983

Published In

Volume / Issue

  • 67 / 4

Start / End Page

  • 343 - 350

PubMed ID

  • 6850653

Pubmed Central ID

  • 6850653

International Standard Serial Number (ISSN)

  • 0361-5960


  • eng

Conference Location

  • United States